Overview
OKYO market data
Price History
OKYO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for OKYO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 SharesBenzinga · Jul 23, 2026, 4:03 PM
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per ShareBenzinga · Jul 23, 2026, 11:01 AM
OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per ShareBenzinga · Jul 22, 2026, 2:02 PM
OKYO Pharma Says Chief Medical Officer, Flavio Mantelli, Purchases 20,000 Of Its Ordinary Shares On NASDAQ At $1.40 Per ShareBenzinga · Jul 22, 2026, 11:08 AM
OKYO Pharma Says Chairman Gabriele Cerrone, Through Panetta Partners, Increases His Holdings With Purchase Of 25,000 Ordinary Shares At $1.40 Per ShareBenzinga · Jul 21, 2026, 11:03 AM
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 PlansGlobenewswire Inc · Jul 20, 2026, 12:02 PM
OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA FeedbackBenzinga · Jul 20, 2026, 11:16 AM
HC Wainwright & Co. Maintains Buy on OKYO Pharma, Lowers Price Target to $5Benzinga · Jul 13, 2026, 10:10 AM
OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCPBenzinga · Jul 8, 2026, 11:10 AM